Keywords: USA, Gastroenterologists, Ulcerative colitis, Abbott, Eisai, Humira, Remicade
US gastroenterologists see significant growth for Abbott/Eisai’s Humira in ulcerative colitis once indication is approved
Article | 29 November 2011
In a recent survey of US gastroenterologists (n=99), BioTrends Research (a Decision Resources company) finds that about two-thirds of the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
